Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Melanoma 1Esophageal Squamous Cell Carcinoma 1

Interventions

pembrolizumab 141Nivolumab 117Ipilimumab 69Cyclophosphamide 34Specimen Handling 30Magnetic Resonance Spectroscopy 28trametinib 23fludarabine 22binimetinib 22Interleukin-2 21dabrafenib 19relatlimab 17encorafenib 17Biopsy 17aldesleukin 16CTLA-4 Antigen 16fludarabine phosphate 15cemiplimab 15atezolizumab 15Radiosurgery 15Opdualag 14Radiotherapy 11lifileucel 10lenvatinib 10Blood Specimen Collection 10spartalizumab 8Paclitaxel 8Cisplatin 8Bevacizumab 8cobimetinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × LGK974 × 1 year × Clear all
NCT01351103 2025-06-13

A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Novartis

Phase 1 Completed
185 enrolled
BreastDermatologicGastrointestinal

Esophageal Squamous Cell Carcinoma, Melanoma, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡